Long-Term Clinical Outcome of Patients Using Risperidone Long-Acting Injectable: The Romanian e-STAR Database


The objectives of e-STAR Romania (NCT00283517) were to collect clinical outcome data of Romania schizophrenia or schizo-affective disorder patients; prospectively to assess the reasons of treatment initiation, medication usage patterns; to document (long-term) clinical efficacy; and to collect safety data, as well as recording 2-year corresponding retrospective data. In total, 378 eligible subjects were enrolled who were initiated either on risperidone long-acting injectable (RLAI) (290) or on an oral antipsychotic (OA) (88) at baseline as required by the local Summary of the Product Characteristics. Data were collected from per patient both retrospectively and prospectively over a 24-month period at 3-month intervals after starting treatment. The results indicated that subjects suffering from schizophrenia or schizo-affective disorder initiated on RLAI were less likely to be hospitalized within the first 24 months after the initiation of treatment. Moreover, subjects treated with RLAI experienced significant improvements in their illness severity and functioning. Discontinuation rates for RLAI were low and doses were stable throughout the 24 months following the initiation of treatment. In addition, the necessity for supplementary concomitant medication was reduced. Adverse events were reported in 20.3% (RLAI) and 11.4% (OA) of the subjects. In general, patients initiated on RLAI and OA at baseline both clinically improved on all assessed parameters but a larger improvement was observed for patients on RLAI. Incidences of reported AEs during the use of RLAI in a naturalistic setting are comparable with those described in clinical studies; however, the incidence of extrapyramidal signs and weight gain was lower than expected.

Share and Cite:

Micluţia, I. , Vrabie, M. and Ciungu, R. (2015) Long-Term Clinical Outcome of Patients Using Risperidone Long-Acting Injectable: The Romanian e-STAR Database. Open Journal of Psychiatry, 5, 153-164. doi: 10.4236/ojpsych.2015.52017.

Conflicts of Interest

The authors declare no conflicts of interest.


[1] Kraepelin, E. (1971) Dementia Praecox and Paraphrenia. Robert E. Krieger Publishing Co., LoCo, Huntington, New York.
[2] Watt, D.C., Katz, K. and Shepherd, M. (1983) The Natural History of Schizophrenia: A 5-Year Prospective Follow-Up of a Representative Sample of Schizophrenics by Means of a Standardized Clinical and Social Assessment. Psychological Medicine, 13, 663-670.
[3] Davis, J.M., Watanabe, M.D., Blake, L. and Metalon, L. (1994) Depot Antipsychotic Drugs. Place in Therapy. Drugs, 47, 741-773. http://dx.doi.org/10.2165/00003495-199447050-00004
[4] Walker, E., Kestler, L., Bollini, A. and Hochman, K.M. (2004) Schizophrenia: Etiology and Course. Annual Review of Psychology, 55, 401-430. http://dx.doi.org/10.1146/annurev.psych.55.090902.141950
[5] Hopper, K., Harrison, G., Janca, A., Bollini, A. and Sartorius, N. (2007) Recovery from Schizophrenia: An International Perspective: A Report from the WHO Collaborative Project, the International Study of Schizophrenia. Oxford University Press, Oxford.
[6] Rabinowitz, J., Levine, S.Z., Haim, R. and Hafner, H. (2007) The Course of Schizophrenia: Progressive Deterioration, Amelioration or Both? Schizophrenia Research, 91, 254-258.
[7] Olesen, A.V. and Mortensen, P.B. (2002) Readmission Risk in Schizophrenia: Selection Explains Previous Findings of a Progressive Course of Disorder. Psychological Medicine, 32, 1301-1307.
[8] Tandon, R., Keshavan, M.S. and Nasrallah, H.A. (2008) Schizophrenia, “Just the Facts” What We Know in 2008. 2. Epidemiology and Etiology. Schizophrenia Research, 102, 1-18.
[9] Levine, S.Z., Lurie, I., Kohn, R. and Levav, I. (2011) Trajectories of the Course of Schizophrenia: From Progressive Deterioration to Amelioration over Three Decades. Schizophrenia Research, 126, 184-191. http://dx.doi.org/10.1016/j.schres.2010.10.026
[10] Jones, P., Rodgers, B., Murray, R. and Marmot, M. (1994) Child Development Risk Factors for Adult Schizophrenia in the British 1946 Birth Cohort. The Lancet, 344, 1398-1402.
[11] Weiser, M., Werbeloff, N., Dohrenwend, B.P., Levav, I., Yoffe, R. and Davidson, M. (2012) Do Psychiatric Registries Include All Persons with Schizophrenia in the General Population? A Population-Based Longitudinal Study. Schizophrenia Research, 135, 187-191.
[12] Buizer-Voskamp, J.E., Laan, W., Staal, W.G., Hennekam, E.A., Aukes, M.F., Termorshuizen, F., Kahn, R.S., Boks, M.P. and Ophoff, R.A. (2011) Paternal Age and Psychiatric Disorders: Findings from a Dutch Population Registry. Schizophrenia Research, 129, 128-132.
[13] Jorgensen, L., Ahlbom, A., Allebeck, P. and Dalman, C. (2010) The Stockholm Non-Affective Psychoses Study (Snaps): The Importance of Including Out-Patient Data in Incidence Studies. Acta Psychiatrica Scandinavica, 121, 389-392. http://dx.doi.org/10.1111/j.1600-0447.2009.01500.x
[14] Geddes, J.R. and Kendell, R.E. (1995) Schizophrenic Subjects with No History of Admission to Hospital. Psychological Medicine, 25, 859-868. http://dx.doi.org/10.1017/S003329170003511X
[15] Patel, M.X. and David, A.S. (2007) Medication Adherence: Predictive Factors and Enhancement Strategies. Psychiatry, 6, 357-361. http://dx.doi.org/10.1016/j.mppsy.2007.06.003
[16] Correll, C.U. (2013) Addressing Barriers to Using Long-Acting Injectable Antipsychotics and Appropriately Monitoring Antipsychotic Adverse Events. Journal of Clinical Psychiatry, 74, e16.
[17] Velligan, D.I., Weiden, P.J., Sajatovic, M., Scott, J., Carpenter, D., Ross, R. and Docherty, J.P. (2009) The Expert Consensus Guideline Series: Adherence Problems in Patients with Serious and Persistent Mental Illness. Journal of Clinical Psychiatry, 70, 1-48. http://dx.doi.org/10.4088/JCP.7090su1cj
[18] Moller, H.J. (2005) Antipsychotic Agents. Gradually Improving Treatment from the Traditional Oral Neuroleptics to the First Atypical Depot. European Psychiatry, 20, 379-385.
[19] Kane, J.M. (2007) Treatment Adherence and Long-Term Outcomes. CNS Spectrums, 12, 21-26.
[20] Acosta, F.J., Ramallo-Farina, Y. and Siris, S.G. (2014) Should Full Adherence Be a Necessary Goal in Schizophrenia? Full versus Non-Full Adherence to Antipsychotic Treatment. Comprehensive Psychiatry, 55, 33-39. http://dx.doi.org/10.1016/j.comppsych.2013.09.005
[21] Olivares, J.M., Rodriguez-Morales, A., Diels, J., Povey, M., Jacobs, A., Zhao, Z., Lam, A., Villalobos Vega, J.C., Cuellar, J.A., de Castro, F.J., et al. (2009) Long-Term Outcomes in Patients with Schizophrenia Treated with Risperidone Long-Acting Injection or Oral Antipsychotics in Spain: Results from the Electronic Schizophrenia Treatment Adherence Registry (e-STAR). European Psychiatry, 24, 287-296. http://dx.doi.org/10.1016/j.eurpsy.2008.12.002
[22] Rosillon, D., Caleo, S., Farmer, D., Ingham, M. and Jacobs, A. (2005) The Electronic Schizophrenia Treatment Adherence Registry—e-STAR: Baseline Results for Germany, Spain and Australia (Abstract). Value in Health, 8, 403. http://dx.doi.org/10.1016/S1098-3015(10)63094-X
[23] Naber, D., Mehnert, A., Rosillon, D., Farmer, D., Schreiner, A. and Jacobs, A. (2005) The Electronic Schizophrenia Treatment Adherence Registry—e-STAR: Baseline Results for Germany (Abstract). Value in Health, 8, 402-403. http://dx.doi.org/10.1016/S1098-3015(10)63093-8
[24] Peuskens, J., Povey, M., Van der Veken, J., Jacobs, A. and Lam, A. (2006) Patient and Physician Satisfaction with Risperidone Long-Acting Injection: 18-Month Interim Results from the Electronic Schizophrenia Treatment Adherence Registry in Belgium (Abstract). European Psychiatry, 23, S163. http://dx.doi.org/10.1016/j.eurpsy.2008.01.945
[25] Miclutia, I., Junjan, V. and Popescu, C. (2004) Stigma social? ti impactul ei asupra ?ncadr?rii ?n munc? a bolnavilor cu afectiuni psihice. Transylvanian Review of Administrative Sciences, 3, 121-127.
[26] Karagianis, J., Novick, D., Pecenak, J., Haro, J.M., Dossenbach, M., Treuer, T., Montgomery, W., Walton, R. and Lowry, A.J. (2009) Worldwide-Schizophrenia Outpatient Health Outcomes (W-SOHO): Baseline Characteristics of Pan-Regional Observational Data from More than 17,000 Patients. International Journal of Clinical Practice, 63, 1578-1588. http://dx.doi.org/10.1111/j.1742-1241.2009.02191.x
[27] Levine, S.Z., Rabinowitz, J., Faries, D., Lawson, A.H. and Ascher-Svanum, H. (2012) Treatment Response Trajectories and Antipsychotic Medications: Examination of Up to 18 Months of Treatment in the CATIE Chronic Schizophrenia Trial. Schizophrenia Research, 137, 141-146.
[28] Jager, M., Weiser, P., Becker, T., Frasch, K., Langle, G., Croissant, D., Steinert, T., Jaeger, S. and Kilian, R. (2014) Identification of Psychopathological Course Trajectories in Schizophrenia. Psychiatry Research, 215, 274-279. http://dx.doi.org/10.1016/j.psychres.2013.11.031
[29] Tandon, R., Nasrallah, H.A. and Keshavan, M.S. (2009) Schizophrenia, “Just the Facts” 4. Clinical Features and Conceptualization. Schizophrenia Research, 110, 1-23.
[30] Peuskens, J. and Gorwood, P. (2012) How Are We Assessing Functioning in Schizophrenia? A Need for a Consensus Approach. European Psychiatry, 27, 391-395. http://dx.doi.org/10.1016/j.eurpsy.2011.02.013
[31] Olivares, J.M., Emmerson, B., Peuskens, J., Diels, J.K., Caleo, S., Povey, M. and Lam, A. (2007) 12-Month Treatment Discontinuation Rates in Patients with Shizophrenia Treated with Risperidone Long Acting Injection (RLAI): Interim Results from the Electronic Schizophrenia Treatment Adherence Registry Project Conducted in Spain, Australia and Belgium (Abstract). Value in Health, 10, A83.
[32] Fleischhacker, W.W. (2009) Second-Generation Antipsychotic Long-Acting Injections: Systematic Review. British Journal of Psychiatry, 195, S29-S36. http://dx.doi.org/10.1192/bjp.195.52.s29
[33] Leucht, C., Heres, S., Kane, J.M., Kissling, W., Davis, J.M. and Leucht, S. (2011) Oral versus Depot Antipsychotic Drugs for Schizophrenia—A Critical Systematic Review and Meta-Analysis of Randomised Long-Term Trials. Schizophrenia Research, 127, 83-92. http://dx.doi.org/10.1016/j.schres.2010.11.020
[34] Haddad, P.M., Tiihonen, J., Haukka, J., Taylor, M., Patel, M.X. and Korhonen, P. (2001) The Place of Observational Studies in Assessing the Effectiveness of Depot Antipsychotics. Schizophrenia Research, 131, 260-261. http://dx.doi.org/10.1016/j.schres.2011.05.022
[35] Leucht, S., Tardy, M., Komossa, K., Heres, S., Kissling, W., Salanti, G. and Davis, J.M. (2012) Antipsychotic Drugs versus Placebo for Relapse Prevention in Schizophrenia: A Systematic Review and Meta-Analysis. Lancet, 379, 2063-2071. http://dx.doi.org/10.1016/S0140-6736(12)60239-6
[36] Peuskens, J., Olivares, J.M., Hustig, H., Povey, M. and Jacobs, A. (2007) Reduced Polypharmacy in Patients Enrolled in the Electronic Schizophrnia Adherence Registry (eSTAR) and Treated with Risperidone Long-Acting Injection (RLAI) for 6 Months (Abstract). European Psychiatry, 22, S101-S220.
[37] Lindenmayer, J.P., Khan, A., Eerdekens, M., Van Hove, I. and Kushner, S. (2007) Long-Term Safety and Tolerability of Long-Acting Injectable Risperidone in Patients with Schizophrenia or Schizoaffective Disorder. European Neuropsychopharmacology, 17, 138-144.
[38] Moller, H.J. (2006) Long-Acting Risperidone: Focus on Safety. Clinical Therapeutics, 28, 633-651. http://dx.doi.org/10.1016/j.clinthera.2006.05.014
[39] Vincent, D. (2006) Synthèse à partir de cinq études sur l’efficacité et la tolérance de la rispéridone à action prolongée. Annales Médico-Psychologiques, Revue Psychiatrique, 164, 634-641.

Copyright © 2023 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.